Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024


Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2023, on Wednesday, March 13, 2024.

Management will host a conference call at 8:00 a.m. EDT / 12:00 p.m. GMT that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and available on the Investors section of the Silence website at www.silence-therapeutics.com. The webcast will also be archived on the Company's website.

Details of the webcast and conference call:

Webcast link: https://edge.media-server.com/mmc/p/rkramk2y

Conference call registration link: https://register.vevent.com/register/BIa97253e879ff493bb6fe3a99a6ba3532

About Silence Therapeutics 
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLDtm platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include zerlasiran designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and divesiran designed to address rare hematological diseases, including polycythemia vera. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.


These press releases may also interest you

at 18:05
Druva, the first and only at-scale SaaS platform for data security, today announced that its strategic partnership with NEXTGEN Group, a prominent IT distribution and services company, has been extended to include Malaysia and Singapore. This...

at 11:30
Jupiter Ed, a leading Student Information and Learning Management System, has recently achieved the Ed-Fi Alliance Student...

at 10:42
Pudgy Penguins, the IP and brand development company behind the series of globally recognized characters, today...

at 08:25
Al Hassan Ghazi Ibrahim Shaker Co. ("Shaker", the "Group" or the "Company"), Saudi Arabia's leading manufacturer, importer, and distributor of Air Conditioners and Home Appliances, has announced its financial results for the first quarter ended 31...

at 07:12
Zinzino, the global health and wellness brand from Scandinavia, has acquired, through a business asset acquisition, the rights to the distributor database and associated customer register, inventory, and intellectual property of the Luxembourg-based...

at 06:27
New Report - "Industrial Machinery Repair/Aftermarket Services Market, 2024 - 2034" published by Market Decipher shows faster growth in repair and aftermarket services across industries. All three sectors B2C, B2B and B2G are simultaneously growing...



News published on and distributed by: